GlassScriptPhysician profile
Kathy Nobles
NPI 1770952582
$525.43
in general payments reported to CMS, 2019-2025
13 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.32 · 2022: $15.43 · 2023: $18.64 · 2024: $32.30 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $438.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $184.45 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $57.07 | 2025 | Rexulti |
| Abbott Laboratories | $57.02 | 2021-2023 | Agilis Hispro |
| Alkermes, INC. | $46.20 | 2021-2025 | Vivitrol |
| Gilead Sciences, INC. | $36.40 | 2025 | |
| Axsome Therapeutics, INC. | $24.59 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $23.60 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.72 | 2025 | Caplyta |
| Exact Sciences Corporation | $18.00 | 2025 | Cologuard Collection Kit |
| Orexo US, INC. | $17.23 | 2025 | Zubsolv |
| Abiomed | $16.33 | 2024 | Impella |
| Astellas Pharma US INC | $13.52 | 2021 | |
| Lilly USA, LLC | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Nobles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.